ClinicalTrials.Veeva

Menu
M

Medisearch Clinical Trials | Saint Joseph, MO

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

PF-04965842
Upadacitinib
Dupilumab
Povorcitinib
PF-06700841
Baricitinib
JNJ-77242113
Lutikizumab
LY3009104
Ruxolitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

24 of 66 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Placebo
Drug: Baricitinib

Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: DS-7011a
Drug: Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: JNJ-77242113

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling
Hidradenitis Suppurativa
Drug: Lutikizumab
Drug: Placebo

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Active, not recruiting
Hidradenitis Suppurativa
Drug: Placebo
Biological: Lutikizumab

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Placebo
Drug: Povorcitinib

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent parti...

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Drug: Placebo

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Enrolling
Prurigo Nodularis
Drug: Povorcitinib
Drug: Placebo

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Enrolling
Prurigo Nodularis
Drug: Placebo
Drug: Povorcitinib

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Active, not recruiting
Prurigo
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study.The study consists of 3 periods:* Screening period: 2 to 4 weeks.* Tre...

Enrolling
Prurigo Nodularis
Drug: Dupilumab

The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or...

Active, not recruiting
Hidradenitis Suppurativa
Drug: secukinumab

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Trial sponsors

Pfizer logo
AbbVie logo
Lilly logo
Incyte logo
Amgen logo
A
A
Boehringer Ingelheim logo
B
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems